论文部分内容阅读
通过对600例非高危因素病例的非离子型造影剂欧乃派克和离子型造影剂泛影葡胺的CT增强扫描，对二者增强后的影像质量及不良反应进行对比研究。结果显示，两种造影剂在影像质量上无统计学差异（P＞0.05）。两种造影剂均无严重不良反应发生，但其总不良反应发生率欧乃派克组明显低于泛影葡胺组（P＞0.01）．提示两种造影剂均可用于非高危因素患者。
600 cases of non-risk factors in non-ionic contrast agent Omnipaque and ionic contrast agent meglumine diatrizoate CT enhanced scan to compare the two enhanced image quality and adverse reactions were compared. The results showed that the two contrast agents in the image quality was no significant difference (P> 0.05). There was no serious adverse reaction between the two contrast agents, but the incidence of adverse reactions in Omnipeck group was significantly lower than that in the diatrizoate group (P> 0.01). It is suggested that both contrast agents can be used in non-risk patients.